Billerica, MA – Bioprocess and bioscience company Millipore says it plans to acquire Norcross, GA-based life sciences manufacturer Serologicals in a transaction valued at approximately $1.4 billion.
The company says the strategic combination of the two will significantly strengthen its bioscience division in a broad range of high-growth segments such as drug discovery products and services, antibodies, cell biology reagents, and stem cell research. Its bioprocess division will gain a cell culture supplements offering that will facilitate its entry into the $1 billion upstream bioprocessing market.
The acquisition is transformational for Millipore, according to Martin Madaus, its chairman, president, and CEO. “This move will significantly increase our life sciences footprint and will advance many of our strategic objectives,” he adds. “With the addition of Serologicals’ R&D capabilities, we will also be able to pursue new markets and bring together the applications expertise of both companies to generate value for customers.”
Together, the combined organizations will have approximately 5,800 employees. The deal is expected to close at the end of June.